“
“Objectives:
Worldwide, only 5% of all salivary gland tumours are reported in children and 35-50% of these are malignant. According to the Finnish Cancer Registry, 15 children were diagnosed with salivary gland cancer (SGC) during 1990-2009 in Finland. There are no previous studies available on the histopathology, treatment, and survival of patients with these rare malignancies in Finland.
Methods: Retrospective patient and tumour data covering the past 20 years were retrieved from the five University Hospitals in Finland. Ten paediatric SGC patients with a median age of 14 years (range, 9-19 years) and with available adequate patient data were included. The series comprised four boys and six girls. https://www.selleckchem.com/products/z-vad-fmk.html Follow-up time varied from five months to 14 years.
Results: Two patients had a history of a previous www.selleckchem.com/products/azd6738.html malignancy. The majority of cases had a parotid gland cancer (7/10), and mucoepidermoid carcinoma was the most common histological subtype (5/10). All patients presented with Stage I-II disease and were treated surgically with curative intent. One patient with a Stage I mucoepidermoid carcinoma of the parotid
gland received postoperative radiotherapy. No recurrences were encountered and all patients were free of disease at the last follow up.
Conclusions: The individual treatment design for paediatric SGC should follow consistent treatment strategies. All patients in the present study had low-grade tumours with a favourable prognosis. Since paediatric SGC is infrequent worldwide, the diagnostics, treatment, and follow up should be centralized in multidisciplinary Head and Neck Centres. (c) 2012 Elsevier Ireland Ltd. All rights reserved.”
“Objective: To determine the net financial gain or loss for medication therapy management (MTM)
services provided to patients by an independent community pharmacy during AZD6244 16 months of operation.
Design: Retrospective study.
Setting: Independent community pharmacy in Iowa City, IA, from September 1, 2006, to December 31, 2007.
Patients: Patients receiving MTM services during the specified period who had proper documentation of reimbursement for the services.
Intervention: MTM services were provided to the patient and documented by the pharmacist or student pharmacist.
Main outcome measure: Net financial gains or losses for providing MTM services. Sensitivity analyses included costs that might be incurred under various conditions of operation.
Results: 103 initial and 88 follow-up MTM visits were conducted during a 16-month time period. The total cost for these services to the pharmacy was $11,191.72. Total revenue from these services was $11,195.00; therefore, the pharmacy experienced a net financial gain of $3.28.